Why limiting AstraZeneca, Johnson & Johnson coronavirus vaccines over blood clot fears could do more harm than good

• Countries across Europe and the Asia-Pacific have restricted use of both the AstraZeneca and Johnson & Johnson jabs after reports of rare blood clots, despite the risks being minuscule
• Experts warn this may be an overreaction that could prolong the pandemic by slowing down the roll-out of vaccines and fuelling public hesitancy